PT  - JOURNAL ARTICLE
AU  - KOSUKE KASHIWABARA
AU  - HIROSHI SEMBA
AU  - SHINJI FUJII
AU  - SHINSUKE TSUMURA
AU  - RYOTA AOKI
TI  - Difference in Benefit of Chemotherapy Between Small Cell Lung Cancer Patients with Interstitial Pneumonia and Patients with Non-small Cell Lung Cancer
DP  - 2015 Feb 01
TA  - Anticancer Research
PG  - 1065--1071
VI  - 35
IP  - 2
4099  - http://ar.iiarjournals.org/content/35/2/1065.short
4100  - http://ar.iiarjournals.org/content/35/2/1065.full
SO  - Anticancer Res2015 Feb 01; 35
AB  - Background: It is not clear whether there is a difference in benefit of chemotherapy between small cell lung cancer (SCLC) patients with pre-existing idiopathic interstitial pneumonias (IIPs) and non-small cell lung cancer (NSCLC) patients with IIPs. Patients and Methods: We performed a retrospective study of the overall survival (OS) between advanced lung cancer patients with IIPs (n=28) and those without IIPs (n=145). Results: The OS in NSCLC patients with IIPs was shorter than in those without IIPs (median OS, 10.6 vs. 27.9 months, p=0.008) but the OS in SCLC patients with IIPs was not inferior to that of those without IIPs (12.7 vs. 14.8 months, p=0.835). Multivariate analysis showed that the small number of regimens increased the risk of mortality, instead of pre-existing IIPs. Conclusion: The continuation of chemotherapy in SCLC patients with IIPs made it possible to have a similar prognosis to that in those without IIPs.